

Resource Summary Report

Generated by [nidm-terms](#) on Jul 28, 2026

Pfizer Inc.

RRID:SCR_021375

Type: Tool

Proper Citation

Pfizer Inc. (RRID:SCR_021375)

Resource Information

URL: <http://www.pfizer.com/>

Proper Citation: Pfizer Inc. (RRID:SCR_021375)

Description: American multinational pharmaceutical and biotechnology corporation. Develops and produces medicines and vaccines for immunology, oncology, cardiology, endocrinology, and neurology. Company has several blockbuster drugs or products that each generate more than US\$1 billion in annual revenues.

Resource Type: commercial organization

Keywords: Pharmaceutical and biotechnology corporation, medicines and vaccines, immunology, oncology, cardiology, endocrinology, neurology, drugs

Resource Name: Pfizer Inc.

Resource ID: SCR_021375

Record Creation Time: 20220129T080355+0000

Record Last Update: 20260725T190945+0000

Ratings and Alerts

No rating or validation information has been found for Pfizer Inc..

No alerts have been found for Pfizer Inc..

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 57 mentions in open access literature.

Listed below are recent publications. The full list is available at [nidm-terms](#) .

Masri A, et al. (2025) Coexisting Calcific Aortic Stenosis and Transthyretin Cardiac Amyloidosis: Real-World Evaluation of Clinical Characteristics and Outcomes. *Journal of the American Heart Association*, 14(2), e033251.

Halfmann PJ, et al. (2025) Multivalent S2 subunit vaccines provide broad protection against Clade 1 sarbecoviruses in female mice. *Nature communications*, 16(1), 462.

Dummer R, et al. (2025) Longitudinal Genomic Analysis to Fine-tune Targeted Therapy: Results of the Phase II LOGIC 2 Trial in Patients with BRAFV600-Mutant Metastatic Melanoma. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 31(11), 2097.

Rao V, et al. (2025) Convergent and clonotype-enriched mutations in the light chain drive affinity maturation of a public antibody. *bioRxiv : the preprint server for biology*.

Lee SM, et al. (2025) Phase II Open-Label Trial of Brentuximab Vedotin with Pembrolizumab in PD-1-Pretreated Metastatic Non-Small Cell Lung Cancer and Metastatic Cutaneous Melanoma. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 31(5), 848.

Sabaghian H, et al. (2025) Analysis of raltegravir analogs to enhance inhibitory efficiency against HIV integrase. *Scientific reports*, 15(1), 16665.

Wang X, et al. (2024) Assessment of the Effects of Abrocitinib on the Pharmacokinetics of Probe Substrates of Cytochrome P450 1A2, 2B6 and 2C19 Enzymes and Hormonal Oral Contraceptives in Healthy Individuals. *European journal of drug metabolism and pharmacokinetics*, 49(3), 367.

Choueiri TK, et al. (2024) Integrative Analyses of Tumor and Peripheral Biomarkers in the Treatment of Advanced Renal Cell Carcinoma. *Cancer discovery*, 14(3), 406.

Garcia-Pavia P, et al. (2024) REALM-DCM: A Phase 3, Multinational, Randomized, Placebo-Controlled Trial of ARRY-371797 in Patients With Symptomatic LMNA-Related Dilated Cardiomyopathy. *Circulation. Heart failure*, 17(7), e011548.

Rey-Ares L, et al. (2024) Cost-Effectiveness of Bivalent Respiratory Syncytial Virus Prefusion??F (RSVpreF) Vaccine During Pregnancy for Prevention of Respiratory Syncytial Virus Among Infants in Argentina. *Infectious diseases and therapy*, 13(11), 2363.

Hassanin SO, et al. (2024) Combining In Vitro, In Vivo, and Network Pharmacology Assays to Identify Targets and Molecular Mechanisms of Spirulina-Derived Biomolecules against Breast Cancer. *Marine drugs*, 22(7).

Wells N, et al. (2024) A pharmaceutical policy accident: collision of shareholder capitalism and Chinese state capitalism driving the shortage of an essential antibiotic. *Journal of pharmaceutical policy and practice*, 17(1), 2430441.

Hyun Lim S, et al. (2024) COVID-19 vaccine evidence monitoring assisted by artificial Intelligence: An emergency system implemented by the Public Health Agency of Canada to capture and describe the trajectory of evolving pandemic vaccine literature. *Vaccine: X*, 21, 100575.

Ram S, et al. (2024) Quantitative performance assessment of Ultivue multiplex panels in formalin-fixed, paraffin-embedded human and murine tumor specimens. *Scientific reports*, 14(1), 8496.

Chorro L, et al. (2024) Preclinical validation of an Escherichia coli O-antigen glycoconjugate for the prevention of serotype O1 invasive disease. *Microbiology spectrum*, 12(6), e0421323.

Crawford J, et al. (2024) A Phase Ib First-In-Patient Study Assessing the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ponsegromab in Participants with Cancer and Cachexia. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 30(3), 489.

Lytton SD, et al. (2024) The severe acute respiratory syndrome coronavirus-2 (SARS CoV-2) omicron sub-variants in Bangladesh cause mild COVID-19 and associate with similar antibody responses irrespective of natural infection or vaccination history. *Heliyon*, 10(10), e31011.

Karadag AS, et al. (2024) Social Media Use in Dermatology in Turkey: Challenges and Tips for Patient Health. *JMIR dermatology*, 7, e51267.

MacRae CA, et al. (2023) Efficacy and Safety of ARRY-371797 in LMNA-Related Dilated Cardiomyopathy: A Phase 2 Study. *Circulation. Genomic and precision medicine*, 16(1), e003730.

Begier E, et al. (2023) Prospective incidence epidemiology study protocol: conducting active surveillance to assess the burden of Lyme disease (BOLD) in primary care practices in endemic areas of six European countries. *BMJ open*, 13(12), e070903.